Lymphoma TopicsShow More
Emily Dumler had 6 months to live after unsuccessful treatment for non-Hodgkin’s lymphoma, but has been in remission for three years since receiving CAR T-cell therapy.
Follicular lymphoma is a slow-growing cancer which is not curable but instead is considered a long-term, chronic disease.
Diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma, is aggressive, but up to three-quarters of patients are responsive to treatment.
Having lymphoma or breast cancer was linked to a three-times higher risk of developing heart failure within five years of initial diagnosis.
Hear from a doctor on the front lines of research into CAR T-cell therapy, a promising new immunotherapy for treatment-resistant non-Hodgkin’s lymphoma.
Chemotherapy and radiation can successfully treat non-Hodgkin’s lymphoma, but they can cause side effects that last or emerge years after treatment.
What's the key to successful treatment of non-Hodgkin's lymphoma? Understanding your diagnosis and treatment options, according to Dr. Gwen Nichols of the Leukemia & Lymphoma Society. She shares how best to navigate your path forward.
CAR T cell therapy is a new FDA approved immunotherapy for treating non-Hodgkin's lymphoma. Dr. Gwen Nichols explains CAR T's applications, process, and history as a cancer therapy.
Dr. Gwen Nichols advises patients on key factors to look for in their health care team while navigating a non-Hodgkin's lymphoma diagnosis and treatment.
Dr. Gwen Nichols, chief medical officer of the Leukemia & Lymphoma Society discusses major developments and what the future holds for non-Hodgkin's lymphoma treatment.